FIG. 6.

Effect of a HFD on enzymes (arginase 1 and eNOS) affecting NO bioavailability in liver. (A) Simplified schematic showing the role of arginase 1 and eNOS-catalyzed reactions. (B) Top panels: Representative immunoblots of eNOS-P^Ser1177 and total eNOS in liver samples from two separate pairs of control and HFD mice. Results are from groups fed diets for 16 weeks. Bottom panels: Densitometry analysis of eNOS-P^Ser1177 and total eNOS levels along with eNOS-P normalized to total eNOS protein. (C) Top panels: Representative immunoblots of arginase 1 and beta-actin protein in liver samples from two separate pairs of control and HFD mice. Results are from groups fed diets for 16 weeks. Bottom panels: Densitometry analysis of arginase 1 and beta-actin levels along with arginase 1 normalized to beta-actin. Data represent the mean ± SEM for n = 4–8 animals per treatment group, with *p < 0.05, compared with control. NO, nitric oxide; eNOS, endothelial NO synthase; eNOS-P^Ser1177, eNOS phosphorylated at residue Ser 1177; Arg1, arginase 1.